Want to see SE:ARCOMA full AI Analyst Report?
ARCOMA Stock Chart & Stats
kr7.20
-kr0.40(-3.79%)
At close: 4:00 PM EST
kr7.20
-kr0.40(-3.79%)
Day’s Range― - ―
52-Week Rangekr6.16 - kr11.00
Previous CloseN/A
Volume10.05K
Average Volume (3M)22.73K
Market Cap
kr120.19M
Enterprise Valuekr101.42M
Total Cash (Recent Filing)kr33.94M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)31.1
Beta0.19
Next Earnings
Aug 20, 2026EPS Estimate
0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.26
Shares Outstanding14,308,510
10 Day Avg. Volume31,356
30 Day Avg. Volume22,732
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)1.41
Price to Sales (P/S)0.80
P/FCF Ratio5.68
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.55
Revenue Forecast (FY)kr135.00M
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet (zero Debt)Zero debt and a solid equity base materially reduce financial risk and interest burden, giving management flexibility to fund product development, service expansion, or absorb order cycles without relying on external financing. This durability supports long-term operational resilience and strategic optionality.
Robust Cash Generation And Free Cash FlowSustained positive operating and free cash flow provides internal funding for capex, R&D, and working capital, reducing reliance on capital markets. Strong cash conversion and recent free cash flow growth improve the company’s ability to invest in product upgrades and service capacity, supporting durable execution.
Recurring Service Revenue From Installed BaseAn installed-base services model yields repeatable aftermarket revenue and higher customer stickiness, smoothing top-line volatility from system deliveries. Over time, service and spare parts margins can sustain profits and cash flow even if new system sales fluctuate, strengthening long-term revenue visibility.
Bears Say
Declining Revenue GrowthMaterial negative revenue growth erodes scale advantages and threatens ability to expand the installed base that generates recurring service revenue. Persistent top-line declines can compress margins, limit reinvestment capacity, and raise execution risk if the company cannot arrest or reverse the trend.
Volatile Margins And ProfitabilityLarge year-to-year swings in gross margin and earnings reduce earnings quality and forecasting reliability. Structural cost or pricing pressure driving volatility could impair long-term returns and make it harder to translate revenue into sustainable free cash flow, increasing investor and management uncertainty.
Small Scale And Limited DiversificationA very small headcount implies constrained R&D, sales coverage, and geographic reach, raising concentration and execution risks. Limited scale can increase per-unit fixed costs, reduce bargaining power with suppliers/customers, and make growth initiatives or large contracts harder to pursue sustainably.
ARCOMA FAQ
What was Arcoma AB’s price range in the past 12 months?
Arcoma AB lowest stock price was kr6.16 and its highest was kr11.00 in the past 12 months.
What is Arcoma AB’s market cap?
Arcoma AB’s market cap is kr120.19M.
When is Arcoma AB’s upcoming earnings report date?
Arcoma AB’s upcoming earnings report date is Aug 20, 2026 which is in 44 days.
How were Arcoma AB’s earnings last quarter?
Arcoma AB released its earnings results on Apr 23, 2026. The company reported kr0.057 earnings per share for the quarter, missing the consensus estimate of kr0.18 by -kr0.123.
Is Arcoma AB overvalued?
According to Wall Street analysts Arcoma AB’s price is currently Overvalued.
Does Arcoma AB pay dividends?
Arcoma AB does not currently pay dividends.
What is Arcoma AB’s EPS estimate?
Arcoma AB’s EPS estimate is 0.14.
How many shares outstanding does Arcoma AB have?
Arcoma AB has 14,308,510 shares outstanding.
What happened to Arcoma AB’s price movement after its last earnings report?
Arcoma AB reported an EPS of kr0.057 in its last earnings report, missing expectations of kr0.18. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Arcoma AB?
Currently, no hedge funds are holding shares in SE:ARCOMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Arcoma AB
Arcoma AB is a global provider that designs, manufactures, and supplies cutting-edge radiology solutions. Their product line features advanced digital x-ray and radiography systems. These versatile systems are suitable for a wide array of radiographic applications and are utilized across various clinical environments, including general practice, musculoskeletal, thoracic, pediatric, and trauma/resuscitation units. The company distributes its products through a network of OEM partners. Arcoma AB was founded in 1990 and is headquartered in Växjö, Sweden.
Technical Analysis
Clinical Laserthermia Systems AB Class B
―
SpectraCure AB
―
Luxbright AB
―
BrainCool AB
―
Neola Medical AB
―